The scientifically interesting part is not really the surgery itself. Lung transplantation is already an established procedure. The novel aspect is the virology.
Historically, organs from HIV-positive donors were excluded because of concerns about “superinfection”, the recipient acquiring a second strain of HIV from the donor.
HIV is not a single virus but a rapidly evolving population of variants. If the donor’s virus carries mutations conferring resistance to certain antiretroviral drugs, introducing that strain into a recipient could potentially complicate treatment.
Modern HIV medicine has changed the risk-benefit calculation. Current antiretroviral regimens can suppress viral replication to undetectable levels in most patients, and genetic sequencing allows clinicians to characterise the virus present in both donor and recipient. This means the transplant team can assess whether the donor strain contains resistance mutations that would be problematic.
The other major issue is immunosuppression. Every transplant recipient receives drugs that deliberately suppress the immune system to prevent rejection. In the early HIV era, combining HIV infection with pharmacological immunosuppression was considered highly risky. What decades of data have shown, however, is that HIV-positive patients with well-controlled infection often have transplant outcomes approaching those of HIV-negative recipients when managed appropriately.
From a population perspective, the real significance is organ utilisation. There are thousands of people living with HIV who die with otherwise transplantable organs. If those organs can be safely allocated to HIV-positive recipients, the effective donor pool increases. That’s particularly important for lungs, where donor shortages are severe and waiting-list mortality remains substantial.
What’s perhaps most remarkable is how much this reflects advances in molecular biology. Forty years ago clinicians largely viewed HIV status as a binary condition: infected or not infected. Today they can quantify viral load to extraordinarily low levels, sequence viral genomes, identify resistance mutations, monitor CD4 counts, and tailor antiretroviral therapy accordingly.
This transplant is therefore less a triumph of surgery than a demonstration of how precisely HIV can now be characterised and managed.
From a scientific standpoint, the long-term data will be the most valuable part. Researchers will want to know whether donor-derived HIV variants persist, whether resistance patterns change over time, whether rejection rates differ, and whether survival matches that seen in conventional lung transplantation.
One successful operation is a milestone; the real significance will be determined by the outcomes of the next hundred patients.
At first glance, the idea sounds increasingly plausible because of drugs such as lenacapavir.
Modern antiretroviral therapy is now so effective that HIV-positive patients undergoing transplantation can achieve outcomes approaching those of HIV-negative recipients when viral loads are suppressed and CD4 counts are adequate. That alone would have been remarkable a few decades ago.
However, the challenge is that an HIV-positive organ is not simply carrying free virus particles. It may contain HIV-infected donor lymphocytes, tissue macrophages, and latent viral reservoirs embedded within the transplanted tissue itself. HIV’s ability to integrate into the host genome means that preventing infection is not merely a matter of neutralising circulating virus.
Clinically, the closest analogy is perhaps not post-exposure prophylaxis but transplantation from hepatitis C-positive donors into hepatitis C-negative recipients.
For many years, this was considered an unacceptable risk because it deliberately exposed the recipient to a chronic viral infection. The development of highly effective direct-acting antivirals fundamentally altered that risk-benefit calculation.
The difference, however, is that hepatitis C and HIV behave very differently biologically. Hepatitis C does not normally integrate into the host genome or establish the same type of long-lived latent cellular reservoirs. HIV does both. Consequently, preventing HIV transmission in the setting of organ transplantation is likely to be considerably more challenging than preventing hepatitis C transmission.
Another consideration is immunosuppression. Lung transplant recipients typically receive potent immunosuppressive regimens such as tacrolimus, mycophenolate, and corticosteroids. These are specifically designed to suppress T-cell responses and prevent rejection. Unfortunately, those same immune cells play a major role in controlling viral infections. Therefore, any attempt to transplant an HIV-positive organ into an HIV-negative recipient would be occurring under conditions that are biologically favourable to viral establishment.
The type of organ would also matter. A kidney or liver contains relatively few lymphoid cells compared with organs such as the lung. Lungs are heavily populated by resident immune cells and are constantly exposed to the external environment. From a virological perspective, they may represent a particularly challenging organ in which to prevent donor-derived HIV transmission.
One could imagine a future protocol involving pre-exposure treatment with a combination of antiretrovirals, perioperative prophylaxis, post-transplant monitoring with ultrasensitive viral-load assays, resistance testing, and perhaps even molecular techniques designed to detect donor-derived HIV DNA within recipient tissues. Modern medicine possesses many more tools than it did twenty years ago.
The question would ultimately become one of risk versus benefit. For a patient dying on a lung-transplant waiting list, accepting a theoretical risk of HIV acquisition that can potentially be controlled pharmacologically may eventually be viewed differently from how it is today.
At present, however, the major unresolved issue is not whether lenacapavir can suppress HIV replication. It almost certainly can. The issue is whether antiretroviral therapy can completely prevent the establishment of infection when an entire organ containing potentially infected lymphocytes, macrophages, and latent viral reservoirs is transplanted into an immunosuppressed recipient. That is a substantially higher bar, and one for which we currently have very little clinical data.
From a scientific perspective, it’s a fascinating question because it reflects how far HIV medicine has progressed. Thirty years ago the discussion was whether HIV-positive patients should receive transplants at all. Today the question is whether sufficiently effective antiviral therapy might one day allow HIV-positive organs to be transplanted into HIV-negative recipients.
That’s a remarkable shift in the clinical landscape.
Thank you for taking the time to write this thoughtful response. It’s an interesting academic question. Lenacapavir is a capsid inhibitor, so it’s novel in the sense that it prevents the viral capsid from entering the nucleus and dumping all its transcription machinery in there. If by chance the virus does make it in to the nucleus, lenacapavir still prevents viral transcription. So it would almost be like two different systems. You would have this organ that is HIV positive but virologically repressed, and then rest of the organ systems that would theoretically be protected from HIV. Also, if someone with well controlled HIV to the point of undetectable virus, what is the risk of transmission during a transplant to an HIV negative person? I suppose it depends, like you said.
HIV is incredible because in 40 years it went from a guaranteed death sentence to a chronic illness that generally confers a normal lifespan.
undulating-beans | 21 hours ago
The scientifically interesting part is not really the surgery itself. Lung transplantation is already an established procedure. The novel aspect is the virology.
Historically, organs from HIV-positive donors were excluded because of concerns about “superinfection”, the recipient acquiring a second strain of HIV from the donor.
HIV is not a single virus but a rapidly evolving population of variants. If the donor’s virus carries mutations conferring resistance to certain antiretroviral drugs, introducing that strain into a recipient could potentially complicate treatment.
Modern HIV medicine has changed the risk-benefit calculation. Current antiretroviral regimens can suppress viral replication to undetectable levels in most patients, and genetic sequencing allows clinicians to characterise the virus present in both donor and recipient. This means the transplant team can assess whether the donor strain contains resistance mutations that would be problematic.
The other major issue is immunosuppression. Every transplant recipient receives drugs that deliberately suppress the immune system to prevent rejection. In the early HIV era, combining HIV infection with pharmacological immunosuppression was considered highly risky. What decades of data have shown, however, is that HIV-positive patients with well-controlled infection often have transplant outcomes approaching those of HIV-negative recipients when managed appropriately.
From a population perspective, the real significance is organ utilisation. There are thousands of people living with HIV who die with otherwise transplantable organs. If those organs can be safely allocated to HIV-positive recipients, the effective donor pool increases. That’s particularly important for lungs, where donor shortages are severe and waiting-list mortality remains substantial.
What’s perhaps most remarkable is how much this reflects advances in molecular biology. Forty years ago clinicians largely viewed HIV status as a binary condition: infected or not infected. Today they can quantify viral load to extraordinarily low levels, sequence viral genomes, identify resistance mutations, monitor CD4 counts, and tailor antiretroviral therapy accordingly.
This transplant is therefore less a triumph of surgery than a demonstration of how precisely HIV can now be characterised and managed.
From a scientific standpoint, the long-term data will be the most valuable part. Researchers will want to know whether donor-derived HIV variants persist, whether resistance patterns change over time, whether rejection rates differ, and whether survival matches that seen in conventional lung transplantation.
One successful operation is a milestone; the real significance will be determined by the outcomes of the next hundred patients.
Causerae | 19 hours ago
Thanks for explaining
No_Size9475 | 21 hours ago
This was an episode of ER like 30 years ago, glad to see it becoming a reality.
RecklessReds | 14 hours ago
Stories like this make me appreciate how far medical research has come. Really hoping this leads to even more breakthroughs.
mantis_tobaggan-md | 16 hours ago
Here’s my question. What if organs from an HIV positive donor were transplanted into a recipient without HIV who was receiving lenacapavir injections?
undulating-beans | 9 hours ago
The clinical picture is actually quite nuanced.
At first glance, the idea sounds increasingly plausible because of drugs such as lenacapavir.
Modern antiretroviral therapy is now so effective that HIV-positive patients undergoing transplantation can achieve outcomes approaching those of HIV-negative recipients when viral loads are suppressed and CD4 counts are adequate. That alone would have been remarkable a few decades ago.
However, the challenge is that an HIV-positive organ is not simply carrying free virus particles. It may contain HIV-infected donor lymphocytes, tissue macrophages, and latent viral reservoirs embedded within the transplanted tissue itself. HIV’s ability to integrate into the host genome means that preventing infection is not merely a matter of neutralising circulating virus.
Clinically, the closest analogy is perhaps not post-exposure prophylaxis but transplantation from hepatitis C-positive donors into hepatitis C-negative recipients.
For many years, this was considered an unacceptable risk because it deliberately exposed the recipient to a chronic viral infection. The development of highly effective direct-acting antivirals fundamentally altered that risk-benefit calculation.
The difference, however, is that hepatitis C and HIV behave very differently biologically. Hepatitis C does not normally integrate into the host genome or establish the same type of long-lived latent cellular reservoirs. HIV does both. Consequently, preventing HIV transmission in the setting of organ transplantation is likely to be considerably more challenging than preventing hepatitis C transmission.
Another consideration is immunosuppression. Lung transplant recipients typically receive potent immunosuppressive regimens such as tacrolimus, mycophenolate, and corticosteroids. These are specifically designed to suppress T-cell responses and prevent rejection. Unfortunately, those same immune cells play a major role in controlling viral infections. Therefore, any attempt to transplant an HIV-positive organ into an HIV-negative recipient would be occurring under conditions that are biologically favourable to viral establishment.
The type of organ would also matter. A kidney or liver contains relatively few lymphoid cells compared with organs such as the lung. Lungs are heavily populated by resident immune cells and are constantly exposed to the external environment. From a virological perspective, they may represent a particularly challenging organ in which to prevent donor-derived HIV transmission.
One could imagine a future protocol involving pre-exposure treatment with a combination of antiretrovirals, perioperative prophylaxis, post-transplant monitoring with ultrasensitive viral-load assays, resistance testing, and perhaps even molecular techniques designed to detect donor-derived HIV DNA within recipient tissues. Modern medicine possesses many more tools than it did twenty years ago.
The question would ultimately become one of risk versus benefit. For a patient dying on a lung-transplant waiting list, accepting a theoretical risk of HIV acquisition that can potentially be controlled pharmacologically may eventually be viewed differently from how it is today.
At present, however, the major unresolved issue is not whether lenacapavir can suppress HIV replication. It almost certainly can. The issue is whether antiretroviral therapy can completely prevent the establishment of infection when an entire organ containing potentially infected lymphocytes, macrophages, and latent viral reservoirs is transplanted into an immunosuppressed recipient. That is a substantially higher bar, and one for which we currently have very little clinical data.
From a scientific perspective, it’s a fascinating question because it reflects how far HIV medicine has progressed. Thirty years ago the discussion was whether HIV-positive patients should receive transplants at all. Today the question is whether sufficiently effective antiviral therapy might one day allow HIV-positive organs to be transplanted into HIV-negative recipients.
That’s a remarkable shift in the clinical landscape.
mantis_tobaggan-md | an hour ago
Thank you for taking the time to write this thoughtful response. It’s an interesting academic question. Lenacapavir is a capsid inhibitor, so it’s novel in the sense that it prevents the viral capsid from entering the nucleus and dumping all its transcription machinery in there. If by chance the virus does make it in to the nucleus, lenacapavir still prevents viral transcription. So it would almost be like two different systems. You would have this organ that is HIV positive but virologically repressed, and then rest of the organ systems that would theoretically be protected from HIV. Also, if someone with well controlled HIV to the point of undetectable virus, what is the risk of transmission during a transplant to an HIV negative person? I suppose it depends, like you said.
HIV is incredible because in 40 years it went from a guaranteed death sentence to a chronic illness that generally confers a normal lifespan.
RecklessReds | 14 hours ago
Stories like this make me appreciate how far medical research has come. Really hoping this leads to even more breakthroughs.